PRPH2 Antibody

What is PRPH2 and what is its function in retinal photoreceptors?

PRPH2, also known as Retinal Degeneration Slow protein (RDS) or Tetraspanin-22 (TSPAN22), is essential for retina photoreceptor outer segment disk morphogenesis. It plays a crucial role with ROM1 in maintaining outer segment disk structure . The protein is required for the maintenance of retinal outer nuclear layer thickness and for the correct development and organization of the photoreceptor inner segment . PRPH2 is primarily expressed in the rim region of rod outer segment (ROS) disks and functions as an adhesion molecule involved in the stabilization and compaction of outer segment disks .

What are the common applications of PRPH2 antibodies in retinal research?

PRPH2 antibodies are utilized in multiple experimental applications including:

• Western Blot (WB): For detection of denatured PRPH2 protein samples

• Immunohistochemistry (IHC): For detection in paraffin-embedded (IHC-P) or frozen tissue sections (IHC-F)

• Immunofluorescence/Immunocytochemistry (IF/ICC): For cellular localization studies

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection using matched antibody pairs

Specific applications include studying retinal degenerative diseases, investigating ciliary targeting mechanisms, and examining the role of PRPH2 in outer segment disk formation and maintenance .

How should researchers select the appropriate PRPH2 antibody for their experiments?

When selecting a PRPH2 antibody, researchers should consider:

• Target epitope location: N-terminal vs. C-terminal antibodies provide different information, especially when studying truncation mutations

• Species reactivity: Verify cross-reactivity with your experimental species (human, mouse, rat, etc.)

• Application compatibility: Confirm the antibody has been validated for your specific application (WB, IHC, IF/ICC)

• Clonality: Polyclonal antibodies may offer broader epitope recognition, while monoclonal antibodies provide higher specificity

• Host species: Consider potential cross-reactivity issues with secondary antibodies in multi-labeling experiments

For example, when studying the Y285X mutation, antibodies directed to the protein's N-terminus detected reduced levels of full-length PRPH2, while no truncated protein product was detected using C-terminal-directed antibodies .

What specimen preparation methods are recommended for PRPH2 immunohistochemistry?

For optimal PRPH2 detection in immunohistochemistry:

• Fixation: Use formalin/PFA-fixed paraffin-embedded sections or frozen sections depending on epitope sensitivity

• Antigen retrieval: Perform heat-mediated antigen retrieval with citrate buffer pH 6 before IHC staining protocol

• Antibody dilution: Optimize antibody concentration (e.g., 1/2500 dilution has been successful for some PRPH2 antibodies in human cerebral cortex tissue)

• Controls: Include appropriate positive and negative controls to validate staining specificity

• Visualization method: Select appropriate detection system based on your experimental requirements

How can PRPH2 antibodies be used to study PRPH2 mutations and their effects on protein expression?

PRPH2 antibodies are valuable tools for investigating how mutations affect protein expression and localization:

• Epitope selection strategy: Use antibodies targeting different domains to distinguish between truncated and full-length proteins

• Quantitative analysis: Western blotting with N-terminal antibodies can quantify total PRPH2 expression levels

• Comparative analysis: In heterozygous models (e.g., Prph2Y285X/WT), C-terminal antibodies can specifically detect only full-length protein to assess wild-type expression

• Subcellular localization: Immunofluorescence can reveal abnormal trafficking or localization patterns

• Functional correlation: Combine antibody detection with functional assays to correlate protein expression with phenotype severity

Research has shown that in the Prph2Y285X/WT disease model mice, no truncated peripherin-2 was detected at the predicted mobility of 32.6 kDa, and levels of full-length peripherin-2 were reduced more than 2-fold versus wild-type controls .

What approaches can be used to study the relationship between PRPH2 and ROM1 using antibodies?

The PRPH2-ROM1 relationship can be examined through:

• Co-immunoprecipitation: Using PRPH2 antibodies to pull down protein complexes and detect ROM1 association

• Quantitative analysis: Measuring stoichiometric relationships in wild-type versus disease models

• Comparative expression: Examining PRPH2:ROM1 ratios in different genotypes

• Localization studies: Using dual-label immunofluorescence to assess co-localization patterns

• Functional substitution analysis: Determining if excess PRPH2 can compensate for ROM1 deficiency

This data demonstrates that in ROM1-deficient models, PRPH2 expression increases relative to rhodopsin, suggesting ROM1 can be replaced by excess PRPH2 for establishing normal outer segment structure .

How can researchers use PRPH2 antibodies to investigate ciliary targeting mechanisms?

For studying PRPH2 trafficking to the cilium/outer segment:

• Compartment-specific markers: Co-label with markers for different cellular compartments (ER, Golgi, endosomes, cilia)

• TetOn-inducible systems: Implement inducible expression systems in mouse cones to track nascent PRPH2 transport

• Endosomal targeting analysis: Focus on late endosome (LE) labeling, as this is a critical waystation for PRPH2 sorting

• Mutational analysis: Compare ciliary targeting of wild-type versus mutant PRPH2 using specific antibodies

• Trafficking perturbation: Assess PRPH2 localization after disrupting specific trafficking pathways

Research has revealed that newly synthesized PRPH2 is first targeted to the lumen of the late endosome en route to the cilia, and cone dystrophy-causing C-terminal mutations of PRPH2 can block entry of nascent PRPH2 into the cone outer segment .

What considerations should be made when using PRPH2 antibodies in genetically modified animal models?

When working with gene-edited models:

• Epitope preservation: Ensure your genetic modification hasn't altered the antibody epitope

• Validation strategies: Verify antibody specificity in your modified model using appropriate controls

• Background strain effects: Consider how genetic background might influence PRPH2 expression levels

• Developmental timing: Account for age-dependent changes in PRPH2 expression patterns

• Heterozygous vs. homozygous analysis: Compare antibody reactivity across different genotypes

In CRISPR/Cas9-generated models like the Prph2Y285X mice, antibodies directed to different protein regions revealed that homozygous Y285X/Y285X mice showed no detectable peripherin-2 whatsoever, while heterozygous models showed reduced levels of the full-length protein .

How can researchers troubleshoot weak or absent PRPH2 signal in Western blots?

For improving PRPH2 detection in Western blots:

• Sample preparation: Ensure complete solubilization of membrane proteins using appropriate detergents

• Loading controls: Use photoreceptor-specific loading controls when comparing different retinal samples

• Transfer conditions: Optimize transfer parameters for tetraspanin proteins (which can be difficult to transfer)

• Blocking optimization: Test different blocking agents to reduce background while preserving specific signal

• Antibody concentration: Titrate primary antibody concentration to determine optimal working dilution

• Enhanced chemiluminescence: Use high-sensitivity detection systems for low-abundance forms of PRPH2

• Enrichment strategies: Consider isolating outer segments to concentrate PRPH2 before analysis

What are the best approaches for quantifying PRPH2 protein levels in disease models?

For accurate PRPH2 quantification:

• Multiple antibodies: Use antibodies targeting different epitopes to confirm results

• Standardization: Normalize to appropriate housekeeping proteins or total protein loading

• Relative ratios: Calculate PRPH2:rhodopsin or PRPH2:ROM1 ratios for comparative analysis

• Calibration curves: Use recombinant PRPH2 standards for absolute quantification

• Image analysis: Employ software tools with appropriate background correction

• Statistical validation: Analyze multiple biological replicates to account for variability

Research has demonstrated that in Prph2Y285X/WT mice, levels of full-length peripherin-2 were reduced more than 2-fold versus wild-type controls , highlighting the importance of quantitative analysis for understanding disease mechanisms.

How can PRPH2 antibodies be used to study genotype-phenotype correlations in retinal diseases?

PRPH2 antibodies can help establish connections between specific mutations and disease phenotypes by:

• Mutation-specific analysis: Compare protein expression patterns across different PRPH2 mutations

• Tissue-specific effects: Assess differential effects on rods versus cones using cell type-specific markers

• Phenotypic correlation: Link protein expression patterns to clinical/functional phenotypes

• Therapeutic monitoring: Evaluate protein restoration following gene therapy approaches

• Structural-functional analysis: Correlate PRPH2 immunolocalization with outer segment structural abnormalities

Recent research classified 284 PRPH2 variants, including 107 truncation variants and 149 missense variants. The missense variants were predominantly (79.9%) clustered in the intradiscal D2 loop of the peripherin protein , information that should guide epitope selection for antibody-based studies.

What considerations should be made when using PRPH2 antibodies in therapeutic development studies?

When evaluating potential PRPH2-targeted therapies:

• Wild-type vs. mutant detection: Select antibodies that can distinguish therapeutic (wild-type) from endogenous (mutant) PRPH2

• Dose-response assessment: Quantify PRPH2 levels to determine therapeutic efficacy at different intervention levels

• Subcellular localization: Verify proper trafficking and localization of supplemented PRPH2

• Structural recovery analysis: Correlate PRPH2 expression with outer segment structural improvements

• Functional correlation: Assess whether protein restoration correlates with functional rescue

Research has shown that supplementation with extra wild-type Prph2 protein can elicit improvements in Prph2 protein levels and rod outer segment structure but may not provide functional rescue in rods or cones , suggesting that elimination of mutant protein may be a pre-requisite for therapeutic success.

How can PRPH2 antibodies be employed in studies of novel molecular mechanisms of pattern dystrophy?

To investigate molecular mechanisms underlying PRPH2-associated pattern dystrophies:

• Disulfide bonding analysis: Study intramolecular disulfide linkages in the D2 loop using non-reducing conditions

• Gain-of-function detection: Look for stable mutant PRPH2 forms that may exert toxic effects

• Structure-function correlation: Link specific molecular defects to pattern dystrophy phenotypes

• Oligomerization studies: Examine how mutations affect PRPH2-PRPH2 and PRPH2-ROM1 interactions

• Disease pathway analysis: Identify downstream effects of PRPH2 mutations on cellular pathways

Research has revealed that not all interruptions of D2 loop intramolecular disulfide bonding lead to haploinsufficiency-related retinitis pigmentosa; more subtle changes can lead to mutant proteins stable enough to exert gain-of-function defects in rods and cones .

What is the current knowledge about PRPH2 variant classification and how can antibodies contribute to this field?

PRPH2 variant classification knowledge includes:

Antibodies can contribute to variant classification by:

• Functional validation: Determine if variants affect protein expression, stability, or localization

• Missense impact assessment: Evaluate D2 loop mutations' effects on protein structure and function

• Truncation analysis: Verify the presence or absence of predicted truncated proteins

• Modifier effect studies: Assess how variants in other genes (e.g., ROM1) modify PRPH2 phenotypes

• Population-specific analysis: Compare variant effects across different genetic backgrounds

The most frequent PRPH2 variant based on published data is c.514C>T/p.R172G with an allele frequency of 11.6%, while c.828+3A>T is the most frequent truncation variant (6.6%) .

How should researchers design experiments to investigate the late endosomal pathway in PRPH2 trafficking?

For investigating PRPH2 trafficking through the late endosomal pathway:

• Compartment markers: Use antibodies against late endosome markers (e.g., Rab7, LAMP1) for co-localization studies

• C-terminal motif analysis: Focus on multiple C-terminal motifs of PRPH2 that regulate LE and ciliary targeting

• Ubiquitination studies: Examine how ubiquitination affects PRPH2 sorting through LE

• ESCRT component interactions: Investigate binding to ESCRT components like Hrs

• Inducible expression systems: Implement TetOn-inducible systems in mouse cones to track nascent PRPH2 transport

Research has revealed that the late endosome is the main waystation that critically sorts newly synthesized PRPH2 to the cilium, with specific C-terminal motifs of PRPH2 regulating this process through ubiquitination and binding to ESCRT components .

What controls and validation steps are essential when working with PRPH2 antibodies?

Essential controls and validation steps include:

• Knockout/knockdown controls: Use PRPH2-null tissue or cells as negative controls

• Epitope blocking: Pre-incubate antibody with immunizing peptide to confirm specificity

• Multiple antibodies: Validate findings using antibodies targeting different epitopes

• Recombinant protein controls: Use purified PRPH2 as positive control for Western blots

• Cross-reactivity assessment: Test antibody against related proteins (e.g., ROM1) to ensure specificity

• Concentration optimization: Determine optimal antibody concentration for each application

• Secondary antibody controls: Include samples with secondary antibody only to assess background

When testing species and application combinations not previously validated, researchers should perform proper controls to verify that the antibody works as expected in their specific experimental context .